Cergutuzumab amunaleukin

Drug Profile

Cergutuzumab amunaleukin

Alternative Names: CEA-IL2v; RG-7813; RO-6895882

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Roche
  • Class Antineoplastics; Immunoglobulins; Interleukins; Monoclonal antibodies; Recombinant fusion proteins
  • Mechanism of Action Carcinoembryonic antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 07 Oct 2016 Pharmacokinetics data from a phase I trial in Solid tumours (Late-stage disease) presented at the 41st European Society for Medical Oncology Congress (ESMO-2016)
  • 01 Aug 2016 Roche completes a phase I trial in Solid tumours (Late-stage disease) in USA, Denmark, Finland, France, Netherlands, Spain, Switzerland and the UK (NCT02004106)
  • 16 Apr 2016 Pharmacodynamics data from a preclinical study in Solid tumours presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top